Cell Reprogramming and Therapeutics LLC

Cell Reprogramming & Therapeutics LLC is a biotechnology company that specializes in developing cell-based technologies to treat central nervous system disorders. The company utilizes a chemical genetics approach, which employs small, cell-membrane-penetrable substances to reprogram adult somatic cells into specialized neuronal and glial subtypes. This methodology avoids the technical, safety, and ethical concerns associated with traditional genetic reprogramming techniques like viral transduction or nuclear transfer, offering a safer and more precise way to regulate cellular behavior and plasticity.

The company's research primarily aims to create cellular models for drug discovery and toxicity studies, as well as regenerative therapies for conditions such as Parkinson's disease, Alzheimer's, stroke, spinal cord injuries, and brain malignancies. Supported by various federal grants, including awards from the NIH and NSF, the company focuses on clinical-grade manufacturing processes and pre-clinical testing to advance these cell-based solutions toward the marketplace. By targeting the fundamental mechanics of cellular regeneration, the firm seeks to provide innovative, scalable tools for personalized medicine and therapeutic intervention.